GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period
The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. The study will also test the safety and side effects of Ranolazine in patients with T2DM. The effects of ranolazine on your fasting glucagon levels, the amount of glucose and insulin secreted in your blood after a meal, and the amount of time it takes for your stomach to empty will be studied.